BioPharma Reporter
OCTOBER 11, 2022
Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.
Scienmag
NOVEMBER 12, 2020
Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection. Peer-reviewed / Randomised Controlled Trial / People Inhaled delivery of a formulation of a key […].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 19, 2022
Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months, according to new clinical trial data.
Pharma Phorum
SEPTEMBER 7, 2020
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.
The Pharma Data
NOVEMBER 5, 2022
Pfizer and BioNTech Advertise streamlined Clinical Data for OmicronBA.4/BA.5- Immune responses againstBA.4/BA.5
NY Times
MAY 11, 2022
your-feed-science Children and Childhood Coronavirus (2019-nCoV) Vaccination and Immunization Moderna Inc New England Journal of Medicine Coronavirus Omicron Variant Clinical Trials Disease Rates Teenagers and Adolescence Drugs (Pharmaceuticals) Food and Drug Administration United States
Pharmaceutical Technology
AUGUST 24, 2022
More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies.
Scienmag
JANUARY 14, 2021
14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. Medicine & Health Breast Cancer cancer Cell Biology Clinical Trials Genetics Medicine/Health Pharmaceutical ScienceHOUSTON – (Jan.
Pharma Phorum
JANUARY 6, 2023
The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim.
The Pharma Data
AUGUST 16, 2021
Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.
The Pharma Data
NOVEMBER 10, 2020
Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We The interim analysis from the phase 1 trial has been published online at the preprint server, medRxiv.
XTalks
NOVEMBER 6, 2020
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. He explained that by taking the vaccine orally “allows for a mucosal response in the intestine that can trigger signals to eliminate viruses in the body.”. COVID-19 Clinical Trials.
Scienmag
NOVEMBER 18, 2020
Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group Peer-reviewed / Randomised Controlled Trial / People **There will be a UK Science Media Centre briefing at 10.15am UK time on Thursday 19th November about this study. […].
Scienmag
NOVEMBER 17, 2020
Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged 18-59 years recruited in China between 16 April and 5 May 2020 Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged 18-59 years recruited in China […].
XTalks
AUGUST 8, 2022
MiroBio is a private biotech company based in the UK that focuses on developing checkpoint agonist antibodies, which are a new class of therapies that work to restore immune balance in patients with autoimmune and inflammatory diseases. PD-1 is a potent immune inhibitory receptor.
The Pharma Data
MAY 16, 2021
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK.
The Pharma Data
OCTOBER 29, 2021
Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine authority, Zabdeno ® (Ad26.ZEBOV) and Mvabea ® (MVA-BN-Filo), was well permitted and convinced a robust vulnerable response in both healthy grown-ups and grown-ups living with HIV. The Innovative Medicines Initiative (IMI) handed backing through the IMI Ebola Programme to support a number of colleges that initiated multiple clinical trials and other vaccine development conditioning.
Scienmag
OCTOBER 15, 2020
Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate was carried out in China between 29 April and 30 July 2020 and involved more than 600 healthy volunteers. Peer reviewed / Randomised clinical trial / People The Lancet Infectious Diseases: Preliminary results find vaccine candidate based on inactivated SARS-CoV-2 virus is safe and […].
The Pharma Data
APRIL 15, 2022
NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age.
The Pharma Data
JULY 12, 2022
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus.
Scienmag
FEBRUARY 19, 2021
Preclinical tests at UAB last year showed potent systemic and mucosal immune responses in mice after a single intranasal dose. Chemistry AND Physics Clinical Trials Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Pharmaceutical Science Vaccines Virology
XTalks
MARCH 13, 2023
The US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) held a recent town hall where three experts from the regulator provided guidance on how to design and conduct gene therapy clinical trials for rare diseases.
NY Times
MARCH 23, 2022
The company said the vaccine produced a strong immune response in children younger than 6, but proved only about 40 percent effective in preventing symptomatic Covid-19.
Pharma Phorum
MARCH 12, 2021
Sanofi and Translate BIO have begun a clinical trial of their potential mRNA COVID-19 shot, as the French pharma struggles to keep pace with rivals despite its background in vaccines. Clinical trial participants will receive one dose of MRT5500, or two doses 21 days apart.
The Pharma Data
JULY 15, 2021
Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) of Beth Israel Deaconess Medical Center suggest maturation of B-cell response without further boosting.
BioPharma Reporter
FEBRUARY 13, 2023
Scancell has reported preliminary immunogenicity data from its Phase 1 COVIDITY clinical trial: with the plasmid DNA based COVID-19 vaccine candidates inducing immune responses when delivered via needle-free tech.
The Pharma Data
DECEMBER 23, 2020
In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. 24, 2020 07:00 UTC.
Pharma Phorum
NOVEMBER 29, 2022
Number of on-going clinical trials: 14. Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. NeoImmuneTech, Inc. CEO: Dr Se Hwan Yang, PhD.
The Pharma Data
SEPTEMBER 2, 2021
The Phase 3 RENOIR trial of RSVpreF is a global, randomized, double-blind, placebo-controlled study that expects to enroll approximately 30,000 participants 60 years and older.
The Pharma Data
MARCH 31, 2022
A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. director of the Hope Clinic at the Emory Vaccine Center in Atlanta, and Angela Branche, M.D.,
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. .
The Pharma Data
JUNE 26, 2021
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Drug Discovery Today
APRIL 15, 2021
First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial the vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit). 176 volunteers will participate in the clinical trial the safety and immune response read-outs expected in Q2 2021
The Pharma Data
SEPTEMBER 25, 2020
Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune Response Data.
The Pharma Data
MARCH 11, 2021
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial.
The Pharma Data
DECEMBER 29, 2020
29, 2020 — Vaccine maker Novavax, along with federal health researchers, announced Monday that a phase 3 trial will begin on the safety and effectiveness of another COVID-19 vaccine — the fifth shot to reach this final stage of development. TUESDAY, Dec.
BioPharma Reporter
DECEMBER 11, 2020
Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.
XTalks
JANUARY 20, 2021
Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. Moreover, the response did not induce symptoms typical of a food allergy.
The Pharma Data
APRIL 3, 2021
Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Clinical Trails
XTalks
NOVEMBER 22, 2022
In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. There are three stages of type 1 diabetes with stage 3 being the step at which a clinical diagnosis is made.
Scienmag
JUNE 27, 2021
The first human trial has shown no obvious side effects and a good immune response. Study points towards role of gut microbiome in vaccine effectiveness Credit: Image by Dr. Hiroshi Kiyono, CC BY 4.0
Pharma Phorum
FEBRUARY 18, 2021
The aim of the study is to find the smallest amount of SARS-CoV-2 that is needed to cause an infection, see how the immune system reacts to the virus, and to assist in the development of new treatments and vaccines.
XTalks
JUNE 9, 2022
APOB is responsible for synthesizing LDL while PCSK9 facilitates its degradation. Doortje Reijman, trial investigator and research associate in Pediatric Metabolic Diseases and Nephrology at the Amsterdam University Medical Center. The Trial.
Expert insights. Personalized for you.
116 
Let's personalize your content